Lucid Diagnostics Inc.

For the period ended Dec 31, 2024. Filed Mar 24, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 24, 2025

LUCD$0.42+4.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

	Years Ended December 31,
	2024	2023
Revenue	$4,346	$2,428
Operating expenses:
Cost of revenue	7,099	5,979
Sales and marketing	16,463	16,404
General and administrative	20,156	19,254
Amortization of acquired intangible assets	688	2,021
Research and development	5,992	7,252
Total operating expenses	50,398	50,910
Operating loss	(46,052)	(48,482)
Other income (expense):
Interest income	322	424
Interest expense	(26)	(416)
Change in fair value - Senior Secured Convertible Note	5,394	(2,980)
Loss on issue and offering costs - Senior Secured Convertible Note	—	(1,186)
Debt extinguishments loss - Senior Secured Convertible Note	(5,167)	(26)
Other income (expense), net	523	(4,184)
Loss before provision for income tax	(45,529)	(52,666)
Provision for income taxes	—	—
Net loss attributable to Lucid Diagnostics Inc.	$(45,529)	$(52,666)
Less: Deemed dividend on Series A and Series A-1 Convertible Preferred Stock	(7,496)	—
Net loss attributable to Lucid Diagnostics Inc. common stockholders	$(53,025)	$(52,666)
Net loss per share attributable to Lucid Diagnostics Inc. common stockholders - basic and diluted	$(1.05)	$(1.26)
Weighted average common shares outstanding, basic and diluted	50,515,773	41,756,129

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.